Financial reports
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
ARS
2022 FY
Annual report to shareholders
29 Jan 24
10-Q
2023 Q3
Quarterly report
13 Oct 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
Current reports
8-K
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
15 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
8-K
Aileron Therapeutics Announces CEO Transition
15 Mar 24
8-K
Departure of Directors or Certain Officers
1 Mar 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
29 Jan 24
8-K
Other Events
25 Jan 24
8-K/A
Index to Consolidated Financial Statements
11 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Jan 24
Registration and prospectus
S-8
Registration of securities for employees
29 Jan 24
S-3
Shelf registration
29 Jan 24
D
$18.25 mm in equity / options / securities to be acquired, sold $18.25 mm, 15 investors
16 Nov 23
424B5
Prospectus supplement for primary offering
21 Jun 22
S-3
Shelf registration
7 Jun 22
424B5
Prospectus supplement for primary offering
15 Apr 22
S-8
Registration of securities for employees
11 Aug 21
S-8
Registration of securities for employees
24 Mar 21
S-3
Shelf registration
29 Jan 21
424B5
Prospectus supplement for primary offering
29 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
31 Jan 24
DEF 14A
Definitive proxy
29 Jan 24
PRE 14A
Preliminary proxy
19 Jan 24
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
PRE 14A
Preliminary proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
Other
EFFECT
Notice of effectiveness
6 Feb 24
CORRESP
Correspondence with SEC
1 Feb 24
UPLOAD
Letter from SEC
1 Feb 24
EFFECT
Notice of effectiveness
17 Jun 22
CORRESP
Correspondence with SEC
14 Jun 22
UPLOAD
Letter from SEC
14 Jun 22
EFFECT
Notice of effectiveness
10 Feb 21
CORRESP
Correspondence with SEC
5 Feb 21
UPLOAD
Letter from SEC
4 Feb 21
EFFECT
Notice of effectiveness
16 Oct 20
Ownership
SC 13D/A
Satter Muneer A
16 Apr 24
4/A
RICKENBACH JOSEF H VON
10 Apr 24
4/A
Reinhard J. Ambros
10 Apr 24
3
Charles Garner
2 Apr 24
4
JAMES BRIAN WINDSOR
6 Mar 24
SC 13G
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO
5 Mar 24
SC 13D/A
Satter Muneer A
5 Mar 24
4
Reinhard J. Ambros
1 Mar 24
4
RICKENBACH JOSEF H VON
1 Mar 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24